Key Takeaways BSX posted 9% Neuromodulation sales growth in Q3 2025, extending its strong yearly momentum.BSX's Neuromodulation growth was aided by DBS benefits shown in the five-year INTREPID study results.BSX's planned Nalu Medical acquisition broadens its Neuromodulation portfolio into new adjacencies.The rising incidences of chronic pain, neurological disorders and mental health conditions continue to drive the demand for global neuromodulation devices. According to Grand View Research, the market is pr ...